BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han KH, Park JY. Chemotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:682-4. [PMID: 18410601 DOI: 10.1111/j.1440-1746.2008.05444.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Thomas NS, George K, Selvam AAA. Anticancer mechanism of troxerutin via targeting Nrf2 and NF-κB signalling pathways in hepatocarcinoma cell line. Toxicology in Vitro 2019;54:317-29. [DOI: 10.1016/j.tiv.2018.10.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
2 Yuan P, Zheng A, Tang Q. Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway. Cell Biol Int 2020;44:1503-13. [DOI: 10.1002/cbin.11346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Sharma A, Kim E, Mun S, Ji MS, Chung BG, Kim JS. Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma. Dyes and Pigments 2019;163:628-33. [DOI: 10.1016/j.dyepig.2018.12.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
4 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han K. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7. [DOI: 10.1111/j.1478-3231.2012.02811.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
6 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
7 Zhang W, Qian S, Yang G, Zhu L, Zhou B, Wang J, Liu R, Yan Z, Qu X. MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma. Gene 2018;659:22-8. [PMID: 29559347 DOI: 10.1016/j.gene.2018.03.053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
8 Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH, Han KH. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:659-667. [PMID: 20552225 DOI: 10.1007/s00432-010-0917-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
9 Dai HY, Chen HY, Lai WC, Hung MC, Li LY. Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. Oncotarget 2015;6:23807-19. [PMID: 26247632 DOI: 10.18632/oncotarget.4278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]